Latest News and Press Releases
Want to stay updated on the latest news?
-
Molecular Disease Screening Microarray Feasibility Study CompletedInitial Serological Disease Screening FDA 510(k) Submission AcceptedCommencement of EU Expanded Immunohematology Field Trial...
-
JERSEY, Channel Islands, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter...
-
Initial Serological Disease Screening FDA 510k Submission ReceivedCommencement of EU Extended Immunohematology Field Trial Activities JERSEY, Channel Islands, Jan. 10, 2020 (GLOBE NEWSWIRE) --...
-
JERSEY, Channel Islands, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the planned appointment of Peter Buhler as Chief...
-
Chris Lindop to Remain as Executive Vice President Reporting to Franz Walt CEO JERSEY, Channel Islands, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a...
-
JERSEY, Channel Islands, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported...
-
JERSEY, Channel Islands, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Executive Officer,...
-
JERSEY, Channel Islands, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the closing of its previously...
-
JERSEY, Channel Islands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously...
-
JERSEY, Channel Islands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an...